

Measuring Overall Severity of Myasthenia Gravis (MG): Evidence for the Added Value of the MG Symptoms PRO

Supplementary Material #3: Distribution of core MG Symptom on the overall symptom severity continuum

Authors:

Antoine Regnault; Modus Outcomes, A division of THREAD, Lyon, France - ORCID: **0000-0001-8234-2896**

Thomas Morel; UCB Pharma, Brussels, Belgium - ORCID:**0000-0002-0690-5359**


Christine de la Loge; PCOM Analytics, Avallon, France - ORCID: **0000-0002-5896-5927**

Flora Mazerolle; Modus Outcomes, A division of THREAD, Lyon, France - ORCID: **0000-0002-3854-632X**

Henry J. Kaminski; Department of Neurology & Rehabilitation Medicine, George Washington University; Washington, DC, USA - ORCID: **0000-0002-8195-0141**

Ali A. Habib; Department of Neurology, University of California, Irvine, California - ORCID: **0000-0003-3432-9747**

Correspondence: Thomas Morel; Thomas.Morel@ucb.com – UCB Pharma SRL, Allée de la Recherche, 60, 1070 Brussels, Belgium



Distribution of MG0002 individual assessments (upper panel – in grey) and MG symptom severity outcome measure items on MG symptom severity measurement continuum organized by core MG symptom (N=541 assessments from 43 unique patients)